

**UK**

## **ELOCON CREAM AND OINTMENT**

### **ABRIDGED PRESCRIBING INFORMATION**

**Uses:** Elocon products contain mometasone furoate 0.1% w/w, a synthetic topical corticosteroid. Elocon Cream and Ointment are indicated for the treatment of inflammatory and pruritic manifestations of psoriasis (excluding widespread plaque psoriasis) and atopic dermatitis.

**Dosage:** A thin film of Elocon cream or ointment should be applied to the affected areas of skin once daily.

**Contraindications, Precautions etc.:** *Contraindications:* Facial rosacea, acne vulgaris, perioral dermatitis, perianal and genital pruritus, napkin eruptions, bacterial, viral and fungal infections, varicella, tuberculosis, syphilis or post-vaccine reactions. Hypersensitivity to mometasone furoate or to other corticosteroids. *Precautions:* Elocon treatment should be discontinued if irritation or sensitisation develop or in the presence of infection not adequately controlled by antifungal or antibacterial therapy. Courses on the face or in children should be restricted to 5 days; long term continuous therapy should be avoided in all patients and occlusion should not be used. Use in psoriasis may result in rebound relapse due to tolerance, risk of generalised pustular psoriasis or local systemic toxicity due to impaired barrier function of skin. Careful supervision is important. Elocon topical preparations are not for ophthalmic use. There is inadequate evidence of safety in human pregnancy. Corticosteroids may carry a very small risk of abnormalities in foetal development. The cream and ointment contain propylene glycol which may cause local skin irritation. The cream also contains stearyl alcohol which may cause local skin reactions (e.g. contact dermatitis).

**Side Effects:** Local reactions include paresthesia, burning, pruritus, tingling, stinging, application site reactions, bacterial infection, folliculitis, furunculosis, allergic contact dermatitis, hypopigmentation, hypertrichosis, secondary infection, striae, acneiform reactions and signs of skin atrophy. Paediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced hypothalamic-pituitary-adrenal axis suppression and Cushing's Syndrome. Other less common and rarely reported side effects are listed in the SPC.

**Presentations:** Elocon Cream 30g or 100g; Elocon Ointment 30g or 100g.

**Basic NHS Price:** Elocon Cream - £4.37 (30g), £12.58 (100g); Elocon Ointment - £4.32 (30g), £12.44 (100g).

**Marketing Authorisation Numbers:** Elocon Cream – PL 00025/0577; Elocon Ointment - PL 00025/0578.

**Legal Category:** POM.

**Marketing Authorisation Holder:** Merck Sharp & Dohme Limited, Hertford Road, Hoddesdon, Hertfordshire EN11 9BU, UK.

**Please refer to the full SPC text before prescribing this product. Adverse events should be reported. Reporting forms and information can be found at [www.yellowcard.gov.uk](http://www.yellowcard.gov.uk). Adverse events should also be reported to MSD Drug Safety Department on +44 (0)1707 363773.**

**Date of revision of the text:** April 2011

*Elocon C&O/API/UK/04-11/06*